Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Advances in Respiratory Medicine
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Author statement Editorial Policy and Information for Authors

open access

Vol 77, No 2 (2009)
REVIEWS
Published online: 2009-03-16
Submitted: 2013-02-22
View PDF (polish) Download PDF file
Get Citation

Potential role of endothelin in patients with acute pulmonary embolism and chronic thromboembolic pulmonary hypertension

Justyna Pedowska-Włoszek, Maciej Kostrubiec, Piotr Pruszczyk
Pneumonol Alergol Pol 2009;77(2):159-165.

open access

Vol 77, No 2 (2009)
REVIEWS
Published online: 2009-03-16
Submitted: 2013-02-22

Abstract

Endothelins (ET), a family of three peptides of strong vasoconstrictive properties, participate in the regulation of vascular tone and blood flow. The synthesis and degradation of the ET predominantly take place in the pulmonary vasculature. Elevated plasma ET levels were reported in various forms of arterial pulmonary hypertension including chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, clinical studies with nonselective ET receptor antagonist - bosentan reported improvement in functional class in patients with CTEPH. It has been suggested that endothelins may play an important role in acute pulmonary thromboembolism (APE). However, further studies are necessary to verify these observations. In the current paper we discuss a potential role of endothelins in CTEPH and APE.

Abstract

Endothelins (ET), a family of three peptides of strong vasoconstrictive properties, participate in the regulation of vascular tone and blood flow. The synthesis and degradation of the ET predominantly take place in the pulmonary vasculature. Elevated plasma ET levels were reported in various forms of arterial pulmonary hypertension including chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, clinical studies with nonselective ET receptor antagonist - bosentan reported improvement in functional class in patients with CTEPH. It has been suggested that endothelins may play an important role in acute pulmonary thromboembolism (APE). However, further studies are necessary to verify these observations. In the current paper we discuss a potential role of endothelins in CTEPH and APE.

Full Text:

View PDF (polish) Download PDF file
Get Citation

Keywords

endothelins; acute pulmonary embolism; chronic thromboembolic hypertension

About this article
Title

Potential role of endothelin in patients with acute pulmonary embolism and chronic thromboembolic pulmonary hypertension

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 2 (2009)

Pages

159-165

Published online

2009-03-16

Bibliographic record

Pneumonol Alergol Pol 2009;77(2):159-165.

Keywords

endothelins
acute pulmonary embolism
chronic thromboembolic hypertension

Authors

Justyna Pedowska-Włoszek
Maciej Kostrubiec
Piotr Pruszczyk

References (49)
  1. Masaki T. The discovery of endothelins. Cardiovasc Res. 1998; 39(3): 530–533.
    PubMed
  2. Gawlik R, Ziora D, Rogala E, et al. Zawartość endoteliny-1 w popłuczynach oskrzelowo-pęcherzykowych u chorych na wybrane choroby dróg oddechowych. Pneumonol Alergol Pol. 1997; 65: 333–337.
  3. Passowicz-Muszyńska E, Jankowska R, Szeliga W. Stężenia endoteliny w surowicy chorych na astmę oskrzelową atopową. Pneumonol Alergol Pol. 1999; 67: 17–21.
  4. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991; 114(6): 464–469.
    PubMed
  5. Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest. 2007; 131(1): 101–108.
    CrossRefPubMed
  6. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004; 24(3): 353–359.
    CrossRefPubMed
  7. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005; 25(2): 244–249.
    CrossRefPubMed
  8. Galiè N, Torbicki A, Barst R, et al. Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004; 25(24): 2243–2278.
    CrossRefPubMed
  9. Nakano J, Takizawa H, Ohtoshi T, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332(6163): 411–415.
    CrossRefPubMed
  10. Packer M, Greenberg B, Massie B, et al. Deleterious Effects of Hydralazine in Patients with Pulmonary Hypertension. New England Journal of Medicine. 1982; 306(22): 1326–1331.
    CrossRef
  11. Blais V, Fugère M, Denault JB, et al. Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett. 2002; 524(1-3): 43–48.
    PubMed
  12. Battistini B, Dussault P. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Pulm Pharmacol Ther. 1998; 11(2-3): 79–88.
    CrossRefPubMed
  13. Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol Pharm Bull. 2001; 24(11): 1219–1230.
    PubMed
  14. Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004; 61(2): 227–237.
    PubMed
  15. Attinà T, Camidge R, Newby DE, et al. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart. 2005; 91(6): 825–831.
    CrossRefPubMed
  16. Macquin-Mavier I, Levame M, Istin N, et al. Mechanisms of endothelin-mediated bronchoconstriction in the guinea pig. J Pharmacol Exp Ther. 1989; 250(2): 740–745.
    PubMed
  17. Shichiri M, Kato H, Marumo F, et al. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension. 1997; 30(5): 1198–1203.
    PubMed
  18. Thiemermann C, Lidbury PS, Thomas GR, et al. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized rabbit. J Cardiovasc Pharmacol. 1989; 13 Suppl 5: S138–41; discussion S142.
    PubMed
  19. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003; 88(2): 163–166.
    CrossRefPubMed
  20. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem. 1993; 268(25): 19126–19133.
    PubMed
  21. Goldie RG. Endothelin receptor subtypes: distribution and function in the lung. Pulm Pharmacol Ther. 1998; 11(2-3): 89–95.
    CrossRefPubMed
  22. Dupuis J, Cernacek P, Tardif JC, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996; 94(7): 1578–1584.
    PubMed
  23. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008; 31(2): 407–415.
    CrossRefPubMed
  24. Sauvageau S, Thorin E, Caron A, et al. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood). 2006; 231(6): 840–846.
    PubMed
  25. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 1993; 91(4): 1367–1373.
    CrossRefPubMed
  26. Lal H, Woodward B, Williams KI. Investigation of the contributions of nitric oxide and prostaglandins to the actions of endothelins and sarafotoxin 6c in rat isolated perfused lungs. Br J Pharmacol. 1996; 118(8): 1931–1938.
    PubMed
  27. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002; 165(3): 398–405.
    CrossRefPubMed
  28. Hocher B, Schwarz A, Fagan KA, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol. 2000; 23(1): 19–26.
    CrossRefPubMed
  29. Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. Circulation. 2003; 108(23): 2834–2838.
    CrossRefPubMed
  30. Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis. Circulation. 2003; 108(22): 2726–2729.
    CrossRefPubMed
  31. Gurewich V, Cohen ML, Thomas DP. Humoral factors in massive pulmonary embolism: an experimental study. Am Heart J. 1968; 76(6): 784–794.
    PubMed
  32. Sofia M, Faraone S, Alifano M, et al. Endothelin abnormalities in patients with pulmonary embolism. Chest. 1997; 111(3): 544–549.
    PubMed
  33. Schini VB, Hendrickson H, Heublein DM, et al. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol. 1989; 165(2-3): 333–334.
    PubMed
  34. Halim A, Kanayama N, el Maradny E, et al. Endothelin-1 increased immunoreactive von Willebrand factor in endothelial cells and induced micro thrombosis in rats. Thromb Res. 1994; 76(1): 71–78.
    PubMed
  35. Dschietzig T, Laule M, Alexiou K, et al. Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction. Crit Care Med. 1998; 26(3): 510–517.
    PubMed
  36. Simon M, Battistini B, Joo Kim Y, et al. Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism. Respir Physiol Neurobiol. 2003; 138(1): 97–106.
    PubMed
  37. Tsang J, Battistini B, Dussault P, et al. Biphasic release of immunoreactive endothelins following acute pulmonary thromboembolism in pigs. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1): S221–S224.
    PubMed
  38. Lee JH, Chun YG, Lee IC, et al. Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Am J Respir Crit Care Med. 2001; 164(7): 1282–1287.
    CrossRefPubMed
  39. Lee JH, Kim S, Park BH, et al. The effect of a combination of inhaled nitric oxide and an endothelin A-.receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Lung. 2005; 183: 139–149.
  40. Tanus-Santos JE, Gordo WM, Udelsmann A, et al. Nonselective endothelin-receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs. Chest. 2000; 118(1): 175–179.
    PubMed
  41. Tsang JYC, Lamm WJE, Neradilek B, et al. Endothelin receptor blockade does not improve hypoxemia following acute pulmonary thromboembolism. J Appl Physiol (1985). 2007; 102(2): 762–771.
    CrossRefPubMed
  42. Torbicki A, Kurzyna M. Nadciśnienie płucne. In: Szczeklik A. ed. Choroby wewnętrzne. . Medycyna Praktyczna. 2006: 351–359.
  43. Kaczyńska A, Kostrubiec M, Pacho R, et al. Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6 months anticoagulation after the first episode of acute pulmonary embolism. Thromb Res. 2008; 122(1): 21–25.
    CrossRefPubMed
  44. Reesink H, Lutter R, et al. Hemodynamic correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004; 24: 110.
  45. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002; 105(9): 1034–1036.
    PubMed
  46. Bresser P, Pepke-Zaba J, Jaïs X, et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc. 2006; 3(7): 594–600.
    CrossRefPubMed
  47. Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005; 128(4): 2599–2603.
    CrossRefPubMed
  48. Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006; 28(1): 138–143.
    CrossRefPubMed
  49. Jais X, Ghofrani A, Hoeper MM, et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): A randomized, placebo-controlled trial — BENEFIT. Am. J. Respir. Crit. Care Med. 2007; 175: A896.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl